According to the research report titled ‘Global Nuclear Medicine Diagnostics Market Size study, by Type (SPECT radiopharmaceuticals, PET radiopharmaceuticals) Modality (SPECT, PET, Alpha-emitters, Beta-emitters, Brachytherapy) Application (Cardiology, Thyroid, Neurology, Oncology, Others) Procedure (Oncology, Cardiovascular, Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary, others) End User (Hospital and diagnostic centres, and Research institutions) and Regional Forecasts 2021-2027‘, available with Market Study Report, global nuclear medicine diagnostics market is slated to record significant growth over 2021-2027.
 

Factors such as surging number of cancer cases, rising adoption of SPECT and PET modality, increasing awareness of nuclear medicine, and innovations in neurological applications are catalyzing the growth of global nuclear medicine diagnostics market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4006448/
 

Despite the positive outlook, stringent government regulations are likely to hamper the industry expansion over the projected duration.
 

In terms of type, the marketspace is bifurcated into SPECT radiopharmaceuticals, and PET radiopharmaceuticals. Radiopharmaceuticals contain a radioactive chemical used for treating cancer, and cardiac & neurological diseases. The overall radiopharmaceuticals segment is driven by increasing demand for rapid & precise diagnosis. However, short half-life of products coupled with high equipment costs, and hospital budget cuts are hindering the segmental growth.
 

With respect to modality, PET segment of worldwide medicine diagnostics industry is expected grow at a considerable pace over the forecast period, owing to characteristics such as higher accuracy as compared to other diagnostic procedures. It is typically combined with X-ray and computed tomography for enhanced precision.
 

As per expert verbatim, North America industry captured a significant share in global nuclear medicine diagnostics industry in 2019, owing to rising government support for deployment of medical isotopes and high investments in R&D.
 

Meanwhile, Asia Pacific market is expected to register momentous growth over the next six years. This can be attributed to flourishing radiopharmaceuticals segment, which is being driven by increasing elderly population as well as rising awareness of nuclear treatments and molecular imaging.
 

Leading companies in worldwide nuclear medicine diagnostics industry sphere are Mallinckrodt plc, Ion Beam Applications SA (IBA), Advanced Accelerator Applications SA, Nordian A.S., Bracco Group, Bayer AG, Lantheus Medical Imaging, Inc., Curium Pharma, GE Healthcare, and Cardinal Health, Inc. among others.